How to buy halo top stock? Their forecasts range from $20.00 to $60.00. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California. Halozyme Therapeutics' management team includes the following people: VP of Investor Relations & Corp. Communications. Get short term trading ideas from the MarketBeat Idea Engine. Over the past year the S&P 500 is higher by 13.98% while HALO is higher by 98.17%. The P/E ratio of Halozyme Therapeutics is 254.13, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.86. This suggests that the stock has a possible downside of 14.1%. Sr. VP, Gen. Company profile page for Eden Creamery LLC including stock price, company news, press releases, executives, board members, and contact information Currency in USD, Trade prices are not sourced from all markets, The Man Who Bought Amazon at $48 Says Buy TaaS Now. Halo Top is light ice cream that actually tastes like ice cream. HALO is higher by $0.94 from the previous closing price of $29.46 on volume of 1,562,055 shares. Earnings for Halozyme Therapeutics are expected to grow by 81.05% in the coming year, from $0.95 to $1.72 per share. Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Earlier, the stock roared as much as 14.9% to an all-time high of 32.62. MarketBeat's community ratings are surveys of what our community members think about Halozyme Therapeutics and other stocks. Wall Street legend Whitney Tilson says there's a huge new tech trend coming – and he's revealing his #1 pick for free. Shop Target for Halo Top. This is a signs that BULLS are attempting to "absorb" supply. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Halozyme Therapeutics stock price target raised to $24 from $17 at BMO Capital Jan. 9, 2020 at 11:43 a.m. 94.69% of the stock of Halozyme Therapeutics is held by institutions. Find real-time HALO - Halozyme Therapeutics Inc stock quotes, ... Gilead (GILD) Reports Positive Top-Line Data on HIV Candidate. Wall Street analysts have given Halozyme Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Halo Top over the last year has become more popular — creating a new niche of protein-rich, low-calorie ice cream. Halo Top ice cream became America's bestselling grocery store pint two years ago. Company insiders that own Halozyme Therapeutics stock include Connie Matsui, Dimitrios Chondros, Helen Torley, James M Daly, Jeffrey William Henderson, Kenneth J Kelley and Michael J Labarre. Looking for new stock ideas? Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. What's next for the stock? Buy halo stock price you can from brokers or on specialized sites. Halozyme Therapeutics does not currently pay a dividend. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Halozyme Therapeutics' stock is owned by a number of institutional and retail investors. Bottom Line. The company's low-fat and non-fat varieties of ice cream appeal to health and calorie conscious consumers and are made using organic and natural ingredients, enabling users to experience healthy variants of ice cream. Learn more. Experts have chosen 7 stocks out of 220 Zacks Rank #1 Strong Buys that have the highest potential to increase in price … All Deals. The P/E ratio of Halozyme Therapeutics is 254.13, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.91. Analyzing Halozyme Therapeutics (NASDAQ:HALO) stock? Now it's being sold to one of the nation's biggest ice cream manufacturers, Wells Enterprises, owner of … The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. Halozyme Therapeutics (HALO) reported earnings 30 days ago. View which stocks are hot on social media with MarketBeat's trending stocks report. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. Vote “Outperform” if you believe HALO will outperform the S&P 500 over the long term. View which stocks have been most impacted by COVID-19. Your health & safety is our priority, and we're taking COVID-19 very seriously. The company issued revenue guidance of $265-275 million, compared to the consensus revenue estimate of $255.12 million. View analysts' price targets for Halozyme Therapeutics. Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO.". © American Consumer News, LLC dba MarketBeat® 2010-2020. halo top stock are also included in the list of such companies. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. Include out of stock. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Read our response here. Only 2.60% of the stock of Halozyme Therapeutics is held by insiders. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Since then, HALO shares have increased by 123.2% and is now trading at $40.66. Halozyme Therapeutics employs 132 workers across the globe. Counsel, Chief Compliance Officer & Corp. Sec. We take a look at earnings estimates for some clues. Halozyme Therapeutics issued an update on its FY 2020 HALO Stock Summary. Halo Top Keto Chocolate Cheesecake Frozen Dessert - 16oz. Shares of HALO can be purchased through any online brokerage account. Let's find out. To see all exchange delays and terms of use please see disclaimer. $0 – $15. High institutional ownership can be a signal of strong market trust in this company. Halo Top General Information Description. Pre-Market earnings guidance on Monday, November, 23rd. HALO stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Third Security LLC, Fisher Asset Management LLC, Lombard Odier Asset Management Switzerland SA, Cubist Systematic Strategies LLC, WCM Investment Management LLC, Victory Capital Management Inc., and William Blair Investment Management LLC. (Add your “outperform” vote. The biopharmaceutical company earns $-72,240,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. In the past three months, Halozyme Therapeutics insiders have sold more of their company's stock than they have bought. Shop today to find Ice Cream & Frozen Dairy Desserts at incredible prices. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Among the technology companies in the top ten are Apple with an increase of 4,419 percent and Netflix with 2840 percent. HALO has a less percent of analysts bearish on the stock than 14.17% of Pharmaceutical Products stocks. View daily, weekly or … With a price/sales ratio of 27.25, Halozyme Therapeutics Inc has a higher such ratio than 92.94% of stocks in our set. 1 out of 5 & up & up. The company provided earnings per share guidance of 0.90-0.95 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.86. Halozyme (HALO) Q3 Earnings Top, 2020 View Up, Stock Rises Zacks Equity Research November 03, 2020 JNJ Quick Quote JNJ RHHBY Quick Quote RHHBY HALO Quick Quote HALO ARGX Quick Quote … HALO's current price/earnings ratio is 252.67, which is higher than 96.96% of US stocks with positive earnings. Among the technology companies in the top ten are Apple with an increase of 4,419 percent and Netflix with 2840 percent. Post-Market 0.00 (0.00%) Sr. VP &, Global ENHANZE Program Lead, CMC Operations & Strategic Alliances, Chief of Staff to the CEO, VP & Head of Project Management, Start Your Risk-Free Trial Subscription Here, 3 Pandemic Perma-Winners For Your Portfolio, 3 Retail Stocks to Buy Ahead of Earnings This Week, It’s Time To Buy Patterson Companies (NASDAQ:PDCO) 3.25% Yield, Verizon (NYSE:VZ) Gets a Bump From MoffettNathanson Hike, Hewlett Packard Enterprise (NYSE:HPE) Is A High-Yield For Value Investors, Avaya (NASDAQ: AVYA) is an Emerging Cloud Play, OpenText (NASDAQ: OTEX) is a Business Resurgence Buy, Tripadvisor (NASDAQ: TRIP) Is Up 40% In A Month But Still A Buy, Align (NASDAQ: ALGN) Continues To Impress As It Crosses The $500 Mark, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, 7 Stocks It May Be Time To Take Profits On, 7 Stocks to Buy For the Current Housing Boom, 7 Stocks That May Provide the Real Solution to The Coronavirus Puzzle, 7 Stocks That Could Provide a Year-End Rally, Receive Analysts' Upgrades and Downgrades Daily.